» Articles » PMID: 33850265

SCAMP3 is a Mutant EGFR Phosphorylation Target and a Tumor Suppressor in Lung Adenocarcinoma

Overview
Journal Oncogene
Date 2021 Apr 14
PMID 33850265
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain constitutively activate EGFR resulting in lung tumorigenesis. Activated EGFR modulates downstream signaling by altering phosphorylation-driven interactions that promote growth and survival. Secretory carrier membrane proteins (SCAMPs) are a family of transmembrane proteins that regulate recycling of receptor proteins, including EGFR. The potential role of SCAMPs in mutant EGFR function and tumorigenesis has not been elucidated. Using quantitative mass-spectrometry-based phosphoproteomics, we identified SCAMP3 as a target of mutant EGFRs in lung adenocarcinoma and sought to further investigate the role of SCAMP3 in the regulation of lung tumorigenesis. Here we show that activated EGFR, either directly or indirectly phosphorylates SCAMP3 at Y86 and this phosphorylation increases the interaction of SCAMP3 with both wild-type and mutant EGFRs. SCAMP3 knockdown increases lung adenocarcinoma cell survival and increases xenograft tumor growth in vivo, demonstrating a tumor suppressor role of SCAMP3 in lung tumorigenesis. The tumor suppressor function is a result of SCAMP3 promoting EGFR degradation and attenuating MAP kinase signaling pathways. SCAMP3 knockdown also increases multinucleated cells in culture, suggesting that SCAMP3 is required for efficient cytokinesis. The enhanced growth, increased colony formation, reduced EGFR degradation and multinucleation phenotype of SCAMP3-depleted cells were reversed by re-expression of wild-type SCAMP3, but not SCAMP3 Y86F, suggesting that Y86 phosphorylation is critical for SCAMP3 function. Taken together, the results of this study demonstrate that SCAMP3 functions as a novel tumor suppressor in lung cancer by modulating EGFR signaling and cytokinesis that is partly Y86 phosphorylation-dependent.

Citing Articles

Artificial intelligence-measured nodule mass for determining the invasiveness of neoplastic ground glass nodules.

Xiong T, Gan H, Lv F, Zhang X, Fu B, Chu Z Quant Imaging Med Surg. 2024; 14(9):6698-6710.

PMID: 39281163 PMC: 11400670. DOI: 10.21037/qims-24-665.


Homeobox D9 drives the malignant phenotypes and enhances the Programmed death ligand-1 expression in non-small cell lung cancer cells via binding to Angiopoietin-2 promoter.

He J, Jiang M, Liu J, Zhu R, Lv W, Lian R World J Surg Oncol. 2023; 21(1):93.

PMID: 36907878 PMC: 10009994. DOI: 10.1186/s12957-023-02969-z.


Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.

Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J J Hematol Oncol. 2022; 15(1):132.

PMID: 36096856 PMC: 9469622. DOI: 10.1186/s13045-022-01320-5.


SCAMP3 Regulates EGFR and Promotes Proliferation and Migration of Triple-Negative Breast Cancer Cells through the Modulation of AKT, ERK, and STAT3 Signaling Pathways.

Acevedo-Diaz A, Morales-Caban B, Zayas-Santiago A, Martinez-Montemayor M, Suarez-Arroyo I Cancers (Basel). 2022; 14(11).

PMID: 35681787 PMC: 9179572. DOI: 10.3390/cancers14112807.


SCAMP2/5 as diagnostic and prognostic markers for acute myeloid leukemia.

Yue C, Xie S, Zhong J, Zhao H, Lin Z, Zhang L Sci Rep. 2021; 11(1):17012.

PMID: 34426610 PMC: 8382833. DOI: 10.1038/s41598-021-96440-2.


References
1.
Brose M, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R . BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002; 62(23):6997-7000. View

2.
Gazdar A . Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009; 28 Suppl 1:S24-31. PMC: 2849651. DOI: 10.1038/onc.2009.198. View

3.
Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

4.
Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

5.
Pao W, Miller V, Politi K, Riely G, Somwar R, Zakowski M . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3):e73. PMC: 549606. DOI: 10.1371/journal.pmed.0020073. View